Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Simona Duranti"'
Autor:
Ilaria Capasso, Angela Santoro, Emanuela Lucci Cordisco, Emanuele Perrone, Francesca Tronconi, Ursula Catena, Gian Franco Zannoni, Giovanni Scambia, Francesco Fanfani, Domenica Lorusso, Simona Duranti
Publikováno v:
Cancers, Vol 15, Iss 5, p 1400 (2023)
This review provides a comprehensive update on recent evidence regarding gynecologic tumors associated with Lynch Syndrome (LS). Endometrial cancer (EC) and ovarian cancer (OC) are the first and second most common gynecologic malignancies in develope
Externí odkaz:
https://doaj.org/article/efb36a3f86d74a1b8fec8eb58923a7ea
Autor:
Luciano Giacò, Fernando Palluzzi, Davide Guido, Camilla Nero, Flavia Giacomini, Simona Duranti, Emilio Bria, Giampaolo Tortora, Tonia Cenci, Maurizio Martini, Elisa De Paolis, Maria Elisabetta Onori, Maria De Bonis, Nicola Normanno, Giovanni Scambia, Angelo Minucci
Publikováno v:
Cancers, Vol 14, Iss 24, p 6152 (2022)
In January 2022, our institution launched a comprehensive cancer genome profiling program on 10 cancer types using a non-IVD solution named the TruSight Oncology 500 Assay provided by Illumina®. The assay analyzes both DNA and RNA, identifying Singl
Externí odkaz:
https://doaj.org/article/5fc382c2d0e5420191465cbf17292b1a
Autor:
Camilla Nero, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Giovanni Scambia, Domenica Lorusso
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Adjuvant therapy recommendations for endometrial cancer were historically based on the individual patient’s risk of disease recurrence using clinicopathologic factors such as age, stage, histologic subtype, tumor grade, and lymphovascular space inv
Externí odkaz:
https://doaj.org/article/e64346d5cfe641f7b343f61782d72f6a
Autor:
Camilla Nero, Simona Duranti, Flavia Giacomini, Angelo Minucci, Luciano Giacò, Alessia Piermattei, Maurizio Genuardi, Tina Pasciuto, Andrea Urbani, Gennaro Daniele, Domenica Lorusso, Raffaele Pignataro, Giampaolo Tortora, Nicola Normanno, Giovanni Scambia
Publikováno v:
Journal of Personalized Medicine, Vol 12, Iss 10, p 1746 (2022)
The implementation of cancer molecular characterization in clinical practice has improved prognostic re-definition, extending the eligibility to a continuously increasing number of targeted treatments. Broad molecular profiling technologies better th
Externí odkaz:
https://doaj.org/article/bb39bb82586d49c6b51929dd7769c199
Autor:
Paola Fuso, Margherita Muratore, Tatiana D’Angelo, Ida Paris, Luisa Carbognin, Giordana Tiberi, Francesco Pavese, Simona Duranti, Armando Orlandi, Giampaolo Tortora, Giovanni Scambia, Alessandra Fabi
Publikováno v:
Cancers, Vol 14, Iss 9, p 2161 (2022)
Breast cancer is the leading cause of death in the female population and despite significant efforts made in diagnostic approaches and treatment strategies adopted for advanced breast cancer, the disease still remains incurable. Therefore, developmen
Externí odkaz:
https://doaj.org/article/dd784f06762840a78302572ce9c8932f
Autor:
Rosa Falcone, Pasquale Lombardi, Marco Filetti, Simona Duranti, Antonella Pietragalla, Alessandra Fabi, Domenica Lorusso, Valeria Altamura, Francesco Paroni Sterbini, Giovanni Scambia, Gennaro Daniele
Publikováno v:
Cancers, Vol 14, Iss 4, p 889 (2022)
(1) Background: Drug development in oncology is changing rapidly. The aim of the present study was to provide an insight into the features of anti-tumor drugs approved in Europe; (2) Methods: We included all the indications for solid tumors issued by
Externí odkaz:
https://doaj.org/article/df55de9b37304c76b305804d76c2c631
Autor:
Simona Duranti, Alessandra Fabi, Marco Filetti, Rosa Falcone, Pasquale Lombardi, Gennaro Daniele, Gianluca Franceschini, Luisa Carbognin, Antonella Palazzo, Giorgia Garganese, Ida Paris, Giovanni Scambia, Antonella Pietragalla
Publikováno v:
Cancers, Vol 13, Iss 20, p 5198 (2021)
Breast cancer represents the first cause of cancer worldwide and the leading cause of cancer mortality for women. Therefore, new therapies are needed to improve the prognosis of women diagnosed with this disease. In this review, we summarize the new
Externí odkaz:
https://doaj.org/article/50e76add363a49dea77f2a4f489271bc
Autor:
Simona Duranti, Antonella Pietragalla, Gennaro Daniele, Camilla Nero, Francesca Ciccarone, Giovanni Scambia, Domenica Lorusso
Publikováno v:
Cancers, Vol 13, Iss 9, p 2089 (2021)
Human papillomavirus (HPV) infection is the recognized cause of almost all cervical cancers. Despite the reduction in incidence due to a wide use of screening programs and a specific vaccine, the prognosis of cervical cancer remains poor, especially
Externí odkaz:
https://doaj.org/article/4a2dfd382f18419eb3c6c8f0fd147d84
Autor:
Camilla Nero, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Vanda Salutari, Maria Vittoria Carbone, Giovanni Scambia, Domenica Lorusso
Publikováno v:
Cancers, Vol 13, Iss 6, p 1298 (2021)
Ovarian cancer treatment strategy is mainly based on three pillars: cytoreductive surgery, platinum-based chemotherapy, and targeted therapies. The latter in the last decade has provided a remarkable improvement in progression free patients and, hope
Externí odkaz:
https://doaj.org/article/29f8512201fa41eb9caf7e2df8a2e7aa
Autor:
Stefania Gori, Alessandro Inno, Valentina Rossi, Monica Turazza, Elena Fiorio, Alessandra Fabi, Giancarlo Bisagni, Jennifer Foglietta, Daniele Santini, Ida Pavese, Arianna Pellegrino, Alberto Zambelli, Patrizia Vici, Vita Leonardi, Sandro Barni, Silvana Saracchini, Giuseppe Bogina, Fabiana Marchetti, Simona Duranti, Gianluigi Lunardi, Filippo Montemurro
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0156221 (2016)
BACKGROUND:There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. METHODS:Data of 148 consecutive patients treated with lapatinib and capecitabine from M
Externí odkaz:
https://doaj.org/article/4042b5acfdbe4a8995478f850a8f5aab